July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
CRISPR/Cas9-targeted enrichment and long-read sequencing of the Fuchs endothelial corneal dystrophy-associated TCF4 triplet repeat
Author Affiliations & Notes
  • Alice E Davidson
    Institute of Ophthalmology , UCL, London , United Kingdom
  • Nathaniel J Hafford Tear
    Institute of Ophthalmology , UCL, London , United Kingdom
  • Yu-Chih Tsai
    Pacific Biosciences, California, United States
  • Amanda Sadan
    Institute of Ophthalmology , UCL, London , United Kingdom
  • Beatriz Sanchez-Pintado
    Institute of Ophthalmology , UCL, London , United Kingdom
  • Christina Zarouchlioti
    Institute of Ophthalmology , UCL, London , United Kingdom
  • Petra Liskova
    Institute of Ophthalmology , UCL, London , United Kingdom
    Department of Ophthalmology, Charles University and General University Hospital in Prague, Prague, Czechia
  • Stephen J Tuft
    Institute of Ophthalmology , UCL, London , United Kingdom
    Moorfields Eye Hospital, London, United Kingdom
  • Tyson A Clark
    Pacific Biosciences, California, United States
  • Alison J Hardcastle
    Institute of Ophthalmology , UCL, London , United Kingdom
  • Footnotes
    Commercial Relationships   Alice Davidson, None; Nathaniel Hafford Tear, None; Yu-Chih Tsai, Pacific Biosciences (E), Pacific Biosciences (I); Amanda Sadan, None; Beatriz Sanchez-Pintado, None; Christina Zarouchlioti, None; Petra Liskova, None; Stephen Tuft, None; Tyson Clark, Pacific Biosciences (E), Pacific Biosciences (I); Alison Hardcastle, None
  • Footnotes
    Support  Fight for Sight; Academy of Medical Sciences springboard award; Moorfields Eye Charity; National Eye Research Centre; PacBio
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6055. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alice E Davidson, Nathaniel J Hafford Tear, Yu-Chih Tsai, Amanda Sadan, Beatriz Sanchez-Pintado, Christina Zarouchlioti, Petra Liskova, Stephen J Tuft, Tyson A Clark, Alison J Hardcastle; CRISPR/Cas9-targeted enrichment and long-read sequencing of the Fuchs endothelial corneal dystrophy-associated TCF4 triplet repeat. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6055. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To demonstrate the utility of an amplification-free long-read sequencing method to characterise the Fuchs endothelial corneal dystrophy (FECD)-associated intronic TCF4 triplet repeat (termed CTG18.1) at the nucleotide level.

Methods : We applied an amplification-free method, utilising the CRISPR/Cas9 system, in combination with PacBio single molecule real time (SMRT) long-read sequencing, to study CTG18.1. FECD patient samples displaying a diverse range of CTG18.1 allele lengths and zygosity status (n=11) were analysed. A robust data analysis pipeline was developed to effectively filter, align and interrogate CTG18.1 specific reads. We compared these results with a conventional PCR-based short tandem repeat (STR) assay.

Results : CRISPR-guided SMRT sequencing of CTG18.1 provided accurate genotyping information for all samples and phasing was possible for 18/22 alleles sequenced. Repeat length instability was observed for all expanded (≥50 repeats) phased CTG18.1 alleles analysed. Furthermore, higher levels of repeat instability were observed with increased CTG18.1 allele lengths (mode length ≥91 repeats) indicating that expanded alleles behave dynamically.

Conclusions : CRISPR-guided SMRT sequencing of CTG18.1 has revealed novel insights into CTG18.1 length instability and highlights that size estimates provided by conventional genotyping assays (e.g. STR analysis and Southern blot) do not provide a full representation of the dynamic nature of this repeat element in its expanded state. Furthermore, this study provides a framework to improve the molecular diagnostic accuracy for CTG18.1-mediated FECD, which we anticipate will become increasingly important as gene-directed therapies are developed for this common age-related disease.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×